Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612588 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6307729 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL8724654 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8726216 | 0.85 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL2126159 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL677082 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5186811 | 0.83 | PTGS2 (0.97) | PTGS2PTGS1 | |
| SCHEMBL8070399 | 0.81 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL6300780 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8721601 | 0.78 | PTGS2 (0.73) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012052180-A1 | COMBINATIONS COMPRISING DHODH INHIBITORS AND COX INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | WO | claimed |
| EP-2444086-A1 | Combinations comprising DHODH inhibitors and COX inhibitors | Almirall, S.A. (ES) | 2012-04-25 | — | — | EP | claimed |
| CN-114159421-B | Pharmaceutical composition comprising dimethyl fumarate | 阿尔米雷尔有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-11602515-B2 | Pharmaceutical compositions comprising dimethyl fumarate | ALMIRALL, S.A. (ES) | 2023-03-14 | — | — | US | disclosed |
| CN-114159421-A | Pharmaceutical composition comprising dimethyl fumarate | 阿尔米雷尔有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20210330628-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | ALMIRALL, S.A. (ES) | 2021-10-28 | — | — | US | disclosed |
| EP-3079666-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL SA (ES) | 2021-02-03 | — | — | EP | disclosed |
| US-20200197348-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | ALMIRALL, S.A. (ES) | 2020-06-25 | — | — | US | disclosed |
| EP-3656379-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | Almirall S.A. (ES) | 2020-05-27 | — | — | EP | disclosed |
| EP-3641736-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | Almirall, S.A. (ES) | 2020-04-29 | — | — | EP | disclosed |
| CN-110636838-A | Pharmaceutical composition comprising dimethyl fumarate | 阿尔米雷尔有限公司 | 2019-12-31 | — | — | CN | disclosed |
| WO-2018234584-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL, S.A. (ES) | 2018-12-27 | — | — | WO | disclosed |
| US-20160310457-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL, S.A. (ES) | 2016-10-27 | — | — | US | disclosed |
| EP-3079666-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | Almirall S.A. (ES) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086467-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
| WO-2012052180-A1 | COMBINATIONS COMPRISING DHODH INHIBITORS AND COX INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | WO | disclosed |
| EP-2444086-A1 | Combinations comprising DHODH inhibitors and COX inhibitors | Almirall, S.A. (ES) | 2012-04-25 | — | — | EP | disclosed |
| EP-1017685-A1 | NEW 2-(3H)-OXAZOLONE DERIVATIVES | ALMIRALL-PRODESFARMA, S.A. (ES) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999014205-A1 | NEW 2-(3H)-OXAZOLONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11602515-B2 | Pharmaceutical compositions comprising dimethyl fumarate | MGAM, SI, FH | PTGS2 2276/4885PTGS1 1521/4885 |
| US-20160310457-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | MGAM, SI, FH | PTGS2 2237/4885PTGS1 1521/4885 |
| US-20210330628-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | MGAM, SI, FH | PTGS2 2168/4885PTGS1 1359/4885 |
| US-20200197348-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | MGAM, SI, FH | PTGS2 2276/4885PTGS1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.